You are here: Industry Insights > HPAPI

News List

MilliporeSigma Launches New Tech and Expanded ADC Capacity ContractPharma
October 29, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, has launched new technology and expanded capacity to advance ADC therapies.
Novasep Expands HPAPI Manufacturing Capacity contractpharma
May 14, 2021
Novasep has expanded its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans, France site.
Angelini Fine Chemicals Invests in Flow Chemistry & Micro-Reaction Technology contractpharma
May 13, 2021
A confluence of factors is driving the need for a paradigm shift in pharmaceutical manufacturing strategies in order to accelerate R&D pipeline to market.
Enteris BioPharma Completes Expansion of Manufacturing Facility contractpharma
May 12, 2021
Also launches CDMO business for the development and manufacture of difficult to formulate drugs and highly potent compounds.
Inhalation CDMO Vectura Expands HPAPI Capabilities contractpharma
December 15, 2020
Vectura Group, an inhalation contract and development manufacturing organization (CDMO), has expanded its capabilities to handle and develop highly potent active pharmaceutical ingredients (HPAPIs) at its facility in Chippenham, UK.
Lonza Expands HPAPI Capabilities contractpharma
November 20, 2020
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for ...
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgra contractpharma
November 19, 2020
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for ...
Lonza Opens Facility for ADC Payload Manufacturing contractpharma
November 06, 2020
Lonza, a specialty CDMO partner to the biopharma industry, has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site.
Global HPAPI market to grow at CAGR of 8.7 percent by 2026 europeanpharmaceuticalreview
September 30, 2020
A report has said that the highly potent compound market will grow to be worth $32,200 million by the end of 2026.
Importance of sublimation tests when freeze-drying HPAPIs shown in study europeanpharmaceuticalreview
September 28, 2020
Researchers have shown that sublimation tests should be conducted if new components are added to the freeze-drying process of HPAPIs.

Previous page 1 2 3 Next page